Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1983;15(Suppl 2):323S–328S. doi: 10.1111/j.1365-2125.1983.tb05881.x

Assessment of the interaction between mianserin and centrally-acting antihypertensive drugs

H L Elliott, B Whiting, J L Reid
PMCID: PMC1427893  PMID: 6824563

Abstract

1 The interaction between mianserin and centrally-acting antihypertensive drugs was evaluated in normal volunteers and in patients with essential hypertension receiving either clonidine or methyldopa.

2 The administration of the first dose of 20 mg mianserin to the normal volunteers was associated with a significant sedative effect and transient postural hypotension.

3 In the normal volunteers, the blood pressure responses to a single oral dose of 300 μg clonidine were not modified by pretreatment with mianserin. The bradycardia associated with clonidine alone, however, was significantly attenuated.

4 In the patient study, no significant changes in blood pressure control were observed, either after the first dose of 30 mg mianserin or after one and two weeks' continued treatment with mianserin.

5 There is no evidence from these studies that the addition of mianserin therapy results in a clinically significant impairment of the antihypertensive effects of clonidine or methyldopa.

Full text

PDF
323S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baumann P. A., Maître L. Blockade of presynaptic alpha-receptors and of amine uptake in the rat brain by the antidepressant mianserine. Naunyn Schmiedebergs Arch Pharmacol. 1977 Oct;300(1):31–37. doi: 10.1007/BF00505077. [DOI] [PubMed] [Google Scholar]
  2. Briant R. H., Reid J. L., Dollery C. T. Interaction between clonidine and desipramine in man. Br Med J. 1973 Mar 3;1(5852):522–523. doi: 10.1136/bmj.1.5852.522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Burgess C. D., Turner P., Wadsworth J. Cardiovascular responses to mianserin hydrochloride: a comparison with tricyclic antidepressant drugs. Br J Clin Pharmacol. 1978;5 (Suppl 1):21S–28S. [PMC free article] [PubMed] [Google Scholar]
  4. Cairncross K. D. On the peripheral pharmacology of amitriptyline. Arch Int Pharmacodyn Ther. 1965 Apr;154(2):438–448. [PubMed] [Google Scholar]
  5. Delbarre B., Schmitt H. Sedative effects of alpha-sympathomimetic drugs and their antagonism by adrenergic and cholinergic blocking drugs. Eur J Pharmacol. 1971;13(3):356–363. doi: 10.1016/0014-2999(71)90226-3. [DOI] [PubMed] [Google Scholar]
  6. Dollery C. T., Davies D. S., Draffan G. H., Dargie H. J., Dean C. R., Reid J. L., Clare R. A., Murray S. Clinical pharmacology and pharmacokinetics of clonidine. Clin Pharmacol Ther. 1976 Jan;19(1):11–17. doi: 10.1002/cpt197619111. [DOI] [PubMed] [Google Scholar]
  7. Doxey J. C., Everitt J., Metcalf G. Mianserin--an analysis of its peripheral autonomic actions. Eur J Pharmacol. 1978 Sep 1;51(1):1–10. doi: 10.1016/0014-2999(78)90055-9. [DOI] [PubMed] [Google Scholar]
  8. Elliott H. L., McLean K., Sumner D. J., Reid J. L. Pharmacodynamic studies on mianserin and its interaction with clonidine. Eur J Clin Pharmacol. 1981;21(2):97–102. doi: 10.1007/BF00637508. [DOI] [PubMed] [Google Scholar]
  9. Franklin K. B., Herberg L. J. Presynaptic alpha-adenoceptors: the depression of self-stimulation by clonidine and its restoration by piperoxane but not by phentolamine or phenoxybenzamine. Eur J Pharmacol. 1977 May 1;43(1):33–38. doi: 10.1016/0014-2999(77)90157-1. [DOI] [PubMed] [Google Scholar]
  10. Henry D. P., Starman B. J., Johnson D. G., Williams R. H. A sensitive radioenzymatic assay for norepinephrine in tissues and plasma. Life Sci. 1975 Feb 1;16(3):375–384. doi: 10.1016/0024-3205(75)90258-1. [DOI] [PubMed] [Google Scholar]
  11. Iversen L. L. Role of transmitter uptake mechanisms in synaptic neurotransmission. Br J Pharmacol. 1971 Apr;41(4):571–591. doi: 10.1111/j.1476-5381.1971.tb07066.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kobinger W., Walland A. Investigations into the mechanism of the hypotensive effect of 2-(2,6-dichlorphenylamino)-2-imidazoline-HCl. Eur J Pharmacol. 1967 Dec;2(3):155–162. doi: 10.1016/0014-2999(67)90080-5. [DOI] [PubMed] [Google Scholar]
  13. Kopera H. Anticholinergic and blood pressure effects of mianserin, amitriptyline and placebo. Br J Clin Pharmacol. 1978;5 (Suppl 1):29S–34S. [PMC free article] [PubMed] [Google Scholar]
  14. LEISHMAN A. W., MATTHEWS H. L., SMITH A. J. Anatgonism of guanethidine by imipramine. Lancet. 1963 Jan 12;1(7272):112–112. doi: 10.1016/s0140-6736(63)91123-1. [DOI] [PubMed] [Google Scholar]
  15. Langer S. Z. Sixth gaddum memorial lecture, National Institute for Medical Research, Mill Hill, January 1977. Presynaptic receptors and their role in the regulation of transmitter release. Br J Pharmacol. 1977 Aug;60(4):481–497. doi: 10.1111/j.1476-5381.1977.tb07526.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mitchell J. R., Cavanaugh J. H., Arias L., Oates J. A. Guanethidine and related agents. 3. Antagonism by drugs which inhibit the norepinephrine pump in man. J Clin Invest. 1970 Aug;49(8):1596–1604. doi: 10.1172/JCI106377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Rand M. J., Rush M., Wilson J. Some observations on the inhibition of salivation by St 155 [2-(2,6-dichlorophenylamine)-2-imidazoline hydrochloride, Catapres, Catapresan]. Eur J Pharmacol. 1969 Jan;5(2):168–172. doi: 10.1016/0014-2999(69)90025-9. [DOI] [PubMed] [Google Scholar]
  18. Reid J. L., Briant R. H., Dollery C. T. Desmethylimipramine and the hypotensive action of clonidine in the rabbit. Life Sci I. 1973 May 15;12(10):459–467. doi: 10.1016/0024-3205(73)90215-4. [DOI] [PubMed] [Google Scholar]
  19. Reid J. L., Porsius A. J., Zamboulis C., Polak G., Hamilton C. A., Dean C. R. The effects of desmethylimipramine on the pharmacological actions of alpha methyldopa in man. Eur J Clin Pharmacol. 1979 Sep;16(2):75–80. doi: 10.1007/BF00563110. [DOI] [PubMed] [Google Scholar]
  20. Robson R. D., Kaplan H. R., Laforce S. An investigation into the bradycardic effects of ST 155 [2-(2,6-dichlorophenylamino)-2-imidazoline HCl] in the anesthetized dog. J Pharmacol Exp Ther. 1969 Sep;169(1):120–131. [PubMed] [Google Scholar]
  21. Schmitt H., Boissier J. R., Giudicelli J. F., Fichelle J. Cardiovascular effects of 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (ST 155). II. Central sympathetic structures. Eur J Pharmacol. 1968 Mar;2(5):340–346. doi: 10.1016/0014-2999(68)90184-2. [DOI] [PubMed] [Google Scholar]
  22. Schmitt H., Schmitt H. Localization of the hypotenisve effect of 2-(2-6-dichlorophenylamino)-2-imidazoline hydrochloride (St 155, Catapresan). Eur J Pharmacol. 1969 Apr;6(1):8–12. doi: 10.1016/0014-2999(69)90057-0. [DOI] [PubMed] [Google Scholar]
  23. THEOBALD W., BUECH O., KUNZ H. A., MORPURGO C., STENGER E. G., WILHELMI G. VERGLEICHENDE PHARMAKOLOGISCHE UNTERSUCHUNGEN MIT TOFRANIL PERTOFRAN UND INSIDON. Arch Int Pharmacodyn Ther. 1964 Apr 1;148:560–596. [PubMed] [Google Scholar]
  24. Vargaftig B. B., Coignet J. L., de Vos C. J., Grijsen H., Bonta I. L. Mianserin hydrochloride: peripheral and central effects in relation to antagonism against 5-hydroxytryptamine and tryptamine. Eur J Pharmacol. 1971 Nov-Dec;16(3):336–346. doi: 10.1016/0014-2999(71)90036-7. [DOI] [PubMed] [Google Scholar]
  25. WHITE A. G. METHYLDOPA AND AMITRIPTYLINE. Lancet. 1965 Aug 28;2(7409):441–441. doi: 10.1016/s0140-6736(65)90792-0. [DOI] [PubMed] [Google Scholar]
  26. van Spanning H. W., van Zwieten P. A. The interaction between alpha-methyl-dopa and tricyclic antidepressants. Int J Clin Pharmacol Biopharm. 1975 Jan;11(1):65–67. [PubMed] [Google Scholar]
  27. van Spanning H. W., van Zwieten P. A. The interference of tricyclic antidepressants with the central hypotensive effect of clonidine. Eur J Pharmacol. 1973 Dec;24(3):402–404. doi: 10.1016/0014-2999(73)90169-6. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES